Unicycive Therapeutics Submits NDA for Oxylanthanum Carbonate
Unicycive Therapeutics' NDA Submission for Oxylanthanum Carbonate
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a notable name in the biotechnology sector, recently took a significant step by submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). This NDA is for Oxylanthanum Carbonate (OLC), aimed at treating hyperphosphatemia in patients suffering from chronic kidney disease (CKD) who are undergoing dialysis. Unicycive is pursuing FDA approval through the 505(b)(2) regulatory pathway.
Excitement and Expectations from Leadership
Shalabh Gupta, MD, the Chief Executive Officer of Unicycive, expressed enthusiasm about the submission, emphasizing its importance in progressing towards providing OLC to those dealing with hyperphosphatemia. According to Gupta, the data they've gathered suggests that OLC could offer a differentiated therapy that helps manage phosphate levels while significantly reducing the number of pills patients need to take. He highlighted the dedicated efforts of the team, stating they are preparing for a potential launch once the FDA approves OLC. Notably, the FDA granted a waiver for the NDA application’s Prescription Drug User Fee Act (PDUFA) fees, translating to a savings of around $4 million.
Details of the NDA Submission
The comprehensive NDA package is underpinned by data from three clinical studies, which include a Phase 1 study involving healthy volunteers, a bioequivalence study, and a tolerability study focusing on CKD patients on dialysis. This is complemented by several preclinical studies alongside documentation on chemistry, manufacturing, and controls (CMC).
Understanding Oxylanthanum Carbonate (OLC)
Oxylanthanum carbonate is being developed using cutting-edge nanoparticle technology as a next-generation phosphate binding agent. Its primary function is to treat hyperphosphatemia in dialysis patients. With robust patent protections, OLC's promising profile aims to enhance patient compliance by reducing the pill burden, making treatment more manageable. A survey conducted by nephrologists revealed a strong demand for treatments addressing the pill burden, which they identified as a critical unmet need in the field.
Market Potential & Challenges
The global market for managing hyperphosphatemia is projected to surpass $2.5 billion, with more than $1 billion of that revenue expected from the U.S. Despite the presence of various FDA-approved medications, a staggering 75% of dialysis patients in the U.S. fail to meet targeted phosphorus levels as per medical recommendations. This highlights an urgent demand for effective treatment solutions.
Consequences of Hyperphosphatemia
Hyperphosphatemia is a severe condition that affects nearly all patients in End Stage Renal Disease (ESRD). If not treated effectively, it can lead to significant health complications such as secondary hyperparathyroidism (SHPT) and renal osteodystrophy, which are linked to serious bone and cardiovascular problems. There is a critical need to manage hyperphosphatemia as it exacerbates existing risks such as cardiovascular diseases common among those on dialysis, largely due to conditions like diabetes and hypertension.
Effective Management Strategies
The management of hyperphosphatemia involves two primary strategies: dietary phosphorus restriction and the use of oral phosphate binding medications that enhance the elimination of dietary phosphates through fecal means, rather than allowing absorption into the bloodstream.
About Unicycive Therapeutics
Unicycive Therapeutics is at the forefront of innovative biopharmaceutical solutions aimed at tackling kidney diseases. Their lead candidate, OLC, shows promise in addressing the complex challenges posed by hyperphosphatemia in dialysis patients. In addition to this, the company is also advancing UNI-494, a new chemical entity targeting conditions related to acute kidney injury. For more information on Unicycive, reach out via email at ir@unicycive.com or call (650) 543-5470.
Frequently Asked Questions
What is Oxylanthanum Carbonate (OLC)?
OLC is a new drug in development by Unicycive Therapeutics to treat hyperphosphatemia in dialysis patients with CKD.
Why is the NDA important?
The NDA submission is critical as it represents a step towards securing FDA approval to bring OLC to patients who need it.
How does OLC differ from existing treatments?
OLC aims to reduce the pill burden, making it easier for patients to manage their treatment compared to current options.
What impact does hyperphosphatemia have on kidney patients?
Untreated hyperphosphatemia can lead to serious complications including bone disease and cardiovascular issues, increasing mortality risk among CKD patients.
How can patients manage hyperphosphatemia effectively?
Patients can manage hyperphosphatemia by restricting dietary phosphorus intake and using oral phosphate binders to reduce absorption.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Global PET-CT Scanner Market Set for $4.9 Billion Growth
- Coloplast A/S Share Trading Insights for Board and Executives
- BW Offshore Adjusts Convertible Bonds for Shareholders' Dividend
- Procaps Group Outlines Strategic Vision for Future Success
- CenExel Launches Advanced PET Scan Unit for Research
- Altamira Therapeutics Attends H.C. Wainwright Conference 2024
- Healthcare Mobility Solutions Market Foresees Major Growth
- Affiliated Network Providers and Aurora Health Join Forces
- Caristo Diagnostics Recognized as a Quarterfinalist for Digital Health Award
- Fortun Advance Reports Rapid Asset Growth and Appoints New VP
- Semnur Pharmaceuticals and Denali Capital to Merge for Growth
- ThreatHunter.ai Launches Free Cybersecurity Tool for Businesses
- RDE, Inc. Changes Ticker Symbol to GIFT for Growth
- Veterinary Point of Care Diagnostics Market Forecast Growth
- Outlook Therapeutics to Present at Major Investment Conference
- NMI Holdings, Inc. Investor Day Scheduled for November 2024
- LM Funding America, Inc. Gears Up for H.C. Wainwright Conference
- Mount Logan Capital Inc. Expands Workforce with New Hire
- Weatherford Strengthens Digital Portfolio with Datagration Deal
- CVRx Expands Board with New Appointments for Growth
- Avenue Therapeutics Announces Participation in Investor Conferences
- Y-mAbs Therapeutics to Present at Key Investor Conferences
- VCI Global Secures $18 Million Contract for IPO Listings
- Trust Stamp's Direct Offering Brings $2 Million for Growth
- Century Lithium Reports High Purity Lithium Carbonate Results
Recent Articles
- National Police Association Opposes New Liability Insurance Bill
- Coating Additives Market Anticipates Expansive Growth Ahead
- TC BioPharm Expands Patient Dosing in ACHIEVE Clinical Trial
- STRATA Skin Sciences CEO to Speak at H.C. Wainwright Event
- DZS Reports Q2 2024 Financial Performance Highlights
- Flipster Launches Earn Campaign for BTC, ETH, and USDT Rewards
- Ruder Finn Appoints Zack Kass to Lead New AI Advisory Council
- Affimed Names Shawn M. Leland New CEO to Drive Growth
- Revival Gold Revamps Beartrack Earn-In Agreement Terms
- Natural Grocers® Partners with Rodale Institute for Organic Growth
- Filevine Achieves Top Ranking Among Fastest-Growing Firms
- TopBuild CEO to Speak at Jefferies Industrials Conference
- Colliers Expands Portfolio with Pritchard Francis Acquisition
- Save Over £450 on Your Holiday Car Hire with Essential Tips
- Evolution Space Celebrates Successful Sea Launch of Hypersonic Rocket
- Importance of Blood Donations in Sickle Cell Treatments
- Legal Action Initiated for Ford Motor Company (F) Investors
- Citi Highlights Dire Challenges Facing China's Economy
- U.S. Steel Shares Drop Amid Concerns Over Ownership Shift
- Brent Oil Prices Decline Amid Economic Concerns and Disruptions
- TOPDON Unveils Innovative Automotive Diagnostics at Frankfurt
- Results from Recent Riksbank Certificate Auction on September 3
- Quidax Sets Milestone as Nigeria’s First SEC Licensed Exchange
- Introducing the MEGAMINI G1: A Water-Cooled Gaming Revolution
- B2C2 Appoints Cactus Raazi as New US Chief Executive Officer